journal article·2022

Real-time in vivo imaging reveals specific nanoparticle target binding in a syngeneic glioma mouse model

Wenlong Zhang, Xiangyu Chen, Dong Ding, Guoxin Zhang, Ziwei Zhu, XingJiu Yang, Mengyuan Li, Lijun Liang, Xudong Shi, Tie Wang, Ran Gao

Nanoscale· Volume 14· Issue 15
Publisher page

Abstract

Nanomaterial-based drug delivery is a promising strategy for glioma treatment. However, the detailed dynamics of nanoparticles in solid glioma are still a mystery, including their intratumoral infiltration depth, penetration, retention time, and distribution. Revealing these processes in detail requires repeated intravital imaging of the corresponding brain tumor regions over time during glioma growth. Hereby, we established a syngeneic orthotopic cerebral glioma mouse model by combining the chronic cranial window and two-photon microscopy. Thus, we were able to investigate the dynamics of the nanoparticles during long-term glioma growth. Three hours after the intravenous (i.v.) injection of integrin αVβ3 binding conjugated silicon nanoparticles (SNPs-PEG-RGD-FITC), green nanoparticles had already infiltrated the brain glioma, and then more nanoparticles penetrated into the solid brain tumor and were retained for at least 8 days. However, the amount of control SNPs-PEG-FITC that infiltrated into the solid brain tumor was very low. Moreover, we found that SNPs-PEG-RGD-FITC were not only located in the tumor border but could also infiltrate into the core region of the solid tumor. In vitro assay also confirmed the high binding affinity between GL-261-Tdtomato cells and SNPs-PEG-RGD-FITC. Our results indicate that SNPs-PEG-RGD-FITC has high penetration and retention in a solid glioma and our model provides novel ideas for the investigation of nanoparticle dynamics in brain tumors.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Barrier Structure and Function Studies · Glioma Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC), Beijing, 100021, China

State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, Changchun, 130015, China

Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, 100021, China

Life and Health Research Institute, Tianjin University of Technology, Tianjin, 300072, China

References (36)

Show source-provided references
1. Xu · Cancer Lett. · 2020 · 476 · 110.1016/j.canlet.2020.02.002 ↗
2. Daneman · Cold Spring Harbor Perspect. Biol. · 2015 · 7 · a02041210.1101/cshperspect.a020412 ↗
3. Eisenstein · Nature · 2018 · 561 · S4210.1038/d41586-018-06705-6 ↗
4. Galstyan · Nat. Commun. · 2020 · 11 · 70110.1038/s41467-020-14427-5 ↗
5. Galstyan · Nat. Commun. · 2019 · 10 · 385010.1038/s41467-019-11719-3 ↗
6. Peng · Nano Res. · 2017 · 10 · 136610.1007/s12274-017-1472-z ↗
7. Wang · Nanomedicine · 2019 · 16 · 6910.1016/j.nano.2018.11.009 ↗
8. Wang · Nanoscale · 2020 · 12 · 2275410.1039/D0NR06315K ↗
9. Wu · Angew. Chem., Int. Ed. · 2021 · 60 · 1256910.1002/anie.202103027 ↗
10. Pratiwi · Biomedicines · 2020 · 9 · 1010.3390/biomedicines9010010 ↗
11. Fuhrmann · Nat. Neurosci. · 2010 · 13 · 41110.1038/nn.2511 ↗
12. Osswald · Nature · 2015 · 528 · 9310.1038/nature16071 ↗
13. Zhang · Neuro-Oncol. Adv. · 2021 · 3 · iii210.1093/noajnl/vdab071.007 ↗
14. Kienast · Nat. Med. · 2010 · 16 · 11610.1038/nm.2072 ↗
15. von Baumgarten · Clin. Cancer Res. · 2011 · 17 · 619210.1158/1078-0432.CCR-10-1868 ↗
16. Stupp · Lancet Oncol. · 2014 · 15 · 110010.1016/S1470-2045(14)70379-1 ↗
17. Gao · Mol. Pharm. · 2014 · 11 · 104210.1021/mp400751g ↗
18. Zhang · J. Nanobiotechnol. · 2019 · 17 · 2910.1186/s12951-019-0461-7 ↗
19. Martínez-Vélez · Nat. Commun. · 2019 · 10 · 223510.1038/s41467-019-10043-0 ↗
20. Lang · J. Clin. Oncol. · 2018 · 36 · 141910.1200/JCO.2017.75.8219 ↗
21. Garanti · Nanomedicine · 2020 · 15 · 156710.2217/nnm-2020-0035 ↗
22. Mahmoudi · J. Biomater. Appl. · 2021 · 35 · 74310.1177/0885328220949367 ↗
23. Zhao · Mol. Cancer Ther. · 2020 · 19 · 203410.1158/1535-7163.MCT-19-1098 ↗
24. Chen · Nucl. Med. Biol. · 2019 · 68–69 · 2210.1016/j.nucmedbio.2018.11.003 ↗
25. Han · Langmuir · 2017 · 33 · 587910.1021/acs.langmuir.7b01140 ↗
26. Song · ACS Appl. Mater. Interfaces · 2017 · 9 · 2041010.1021/acsami.7b03504 ↗
27. Cai · J. Labelled Compd. Radiopharm. · 2013 · 56 · 26410.1002/jlcr.2999 ↗
28. Hatley · Angew. Chem., Int. Ed. · 2018 · 57 · 329810.1002/anie.201707948 ↗
29. Kording · J. Magn. Reson. Imaging · 2014 · 40 · 131010.1002/jmri.24513 ↗
30. Li · Chem. Soc. Rev. · 2020 · 49 · 227310.1039/C9CS00575G ↗
31. Miura · ACS Nano · 2013 · 7 · 858310.1021/nn402662d ↗
32. Ruan · ACS Appl. Mater. Interfaces · 2017 · 9 · 1774510.1021/acsami.7b03682 ↗
33. Chen · ACS Appl. Mater. Interfaces · 2017 · 9 · 586410.1021/acsami.6b15831 ↗
34. Gu · J. Controlled Release · 2020 · 322 · 3110.1016/j.jconrel.2020.03.009 ↗
35. Iliff · Sci. Transl. Med. · 2012 · 4 · 147ra11110.1126/scitranslmed.3003748 ↗
36. Xie · Science · 2013 · 342 · 37310.1126/science.1241224 ↗